| Name | Title | Contact Details |
|---|
Developing breakthrough medicines for patients with cancer and rare genetic diseases is incredibly important, and so difficult. It takes great science. But it also takes an environment where people care – about the work, about each other, and about patients. At Agios, we`re always looking for the sweet spot between exhilaration and anxiety – while being respectful, kind and connected with each other so we can flourish. At our core, we`re a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients. We`re a science-driven, global organization that`s built a discovery platform on our expertise across three major focus areas: cancer metabolism, rare genetic diseases and metabolic immuno-oncology. And we care. A lot. Patients are counting on us, and we`re driven by a sense of urgency to help. We challenge ourselves to think big and welcome different perspectives and backgrounds. And we deliver. We have two approved oncology precision medicines and multiple first-in-class investigational therapies in development. So far. Through it all, we are propelled by our connections. We believe in our people to be…just who they are. We believe in our work and in each other – in enjoying this journey together so that we can achieve the Other Side of Possible.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health for US, European and other world markets.
Cardinal Health, Inc. is an American multinational health care services company, and the 14th highest revenue generating company in the United States.
Venture Technology Group is a Farmington Hills, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)